GSK's Blenrep (belantamab mafodotin) has shown promising results in the phase III DREAMM-7 trial, outperforming daratumumab in combination with BorDex (bortezomib and dexamethasone) as a second-line treatment for relapsed or refractory multiple myeloma. The trial involved 494 patients who had previously undergone therapy and experienced disease progression.
The independent review board recommended early unblinding of the trial due to the significant improvement in progression-free survival (PFS) observed in the Blenrep arm. Furthermore, the data indicated a positive trend in overall survival (OS).
The primary endpoint of the DREAMM-7 trial, PFS, was met. GSK is conducting further analyses to assess other key measures, including overall survival (OS), duration of response, and rates of minimal residual disease negativity. Hesham Abdullah, leading GSK's team, is preparing to present detailed findings from the interim analysis in the near future.
Blenrep utilizes a mechanism targeting the B-cell maturation antigen (BCMA) to deliver auristatin F, a cytotoxic agent. This innovative approach, incorporating technologies licensed from Seagen Inc. and BioWa Inc., aims to address the challenges of treating multiple myeloma, a disease often manageable but not curable.
The safety profile of Blenrep in the DREAMM-7 trial was consistent with previous data. GSK intends to communicate these findings with health authorities to discuss potential regulatory actions. Stakeholders can consult the European Medicines Agency (EMA) reference guide provided by GSK for detailed safety information regarding Blenrep's use in the European Union.
